Close Menu

NEW YORK (GenomeWeb) – Bristol-Myers Squibb and Boston Medical Center are collaborating on a multi-year research study on biomarkers that indicate sensitivity and resistance to standard-of-care checkpoint inhibitors.

The goal of the study is to identify prognostic and predictive immuno-oncology biomarkers across different cancers. The researchers will explore not only tissue and circulating biomarkers but also the role of the microbiome in predicting benefit from immune checkpoint inhibitors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to NPR, an antibody-based test could identify people who were exposed to SARS-CoV-2 and either didn't develop symptoms or were misdiagnosed.

A sequencing analysis of New York City rats indicates they have adapted to the urban environment there, according to a recent preprint.

Ars Technica reports that a multicellular eukaryotic parasite has lost its mitochondria.

In Science this week: perspective piece says AI can accelerate drug discovery by using genomic and chemical data, and more.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.